VSIG2

Across TCGA pan-cancer cohorts, VSIG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated VSIG2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher VSIG2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated VSIG2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where VSIG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.195	0.768	.006	13	view →
PDAC	DFS	Tertile	All	0.430	0.224	.028	6	view →
LSCC	DFS	Median	All	0.552	0.900	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

VSIG2–LUAD (DFS)

Open the LUAD breakdown →